111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers. Its product portfolio comprises prescription and over-the counter drugs, such as western and traditional Chinese medicinal drugs; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices, including bandages and thermometers; and personal care products, such as skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Drug Mall, including pharmacies and wholesalers; and digital contract sales organization and data services. As of December 31, 2020, it operated 13 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Wuhan, Tianjin, and Kunshan. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. 111, Inc. has strategic partnerships with Bayer Healthcare Co. Ltd.; BeiGene, Ltd.; and Jianming Pharmaceutical Group. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
IPO Year: 2018
Exchange: NASDAQ
Website: 111.com.cn
Citigroup resumed coverage of 111, Inc. with a rating of Buy and set a new price target of $16.00
Maintained Operational Profitability for the Second Consecutive QuarterOperating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoYHeld Positive Operating Cash Flow for Two Consecutive QuartersSHANGHAI, Aug. 29, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Net revenues were RMB3.4 billion (US$471.2 million) and gross segment profit (1) was RMB 207.6 million
SHANGHAI, July 29, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2024, before the U.S. market opens on Thursday, August 29, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 29, 2024 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Second Quarter 2024 Earnings Co
Turned to Quarterly Operational Profitability for the First TimeOperating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoY to 5.8%Achieved Positive Operating Cash FlowSHANGHAI, May 23, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Net revenues were RMB3.5 billion (US$488.7 million) and Gross segment profit (1) was RMB 208.5 million (US$ 28.9 million). Due to
SHANGHAI, April 30, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2024, before the U.S. market opens on Thursday, May 23, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, May 23, 2024 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. First Quarter 2024 Earnings Conference CallRegistration Link: https:/
SHANGHAI, March 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Highlights Net revenues were RMB4.1 billion (US$578.7 million), representing a decrease of 1.0% year-over-year.Gross segment profit (1) was RMB 214.3 million (US$ 30.2 million), decreased by 15.5% year-over-year.Total operating expenses were RMB420.8 million (US$59.3 million), compared to RMB361.9 million in the same quarter of last y
SHANGHAI, March 1, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2023 ended December 31, 2023, before the U.S. market opens on Thursday, March 21, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, March 21, 2024 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Fourth Quarter and Fiscal Year 2023 Unaud
SHANGHAI, Nov. 30, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights Net revenues were RMB3.7 billion (US$502.4 million), representing an increase of 9.5% year-over-year.Gross segment profit (1) was RMB 190.6 million (US$ 26.1 million), decreased by 5.6% year-over-year.Total operating expenses were RMB271.0 million (US$37.2 million), compared to RMB282.7 million in the same quarter of last year. As a percent
SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Highlights Net revenues were RMB3.5 billion (US$479.6 million), representing an increase of 14.5% year-over-year.Gross segment profit(1) increased by 8.3% year-over-year, with B2B segment profit increasing by 11.6% year-over-year.Total operating expenses were RMB249.3million (US$34.4million), compared to RMB271.7 million in the same quarter of last year. A
SHANGHAI, July 31, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2023, before the U.S. market opens on Thursday, August 24, 2023. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 24, 2023 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Second Quarter 2023 Earnings Conference CallRegistration Link: ht
SHANGHAI, June 15, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Net revenues were RMB3.7 billion (US$538.3 million), representing an increase of 23.9% year-over-year.Gross segment profit (1) increased by 22.7% year-over-year, with B2B segment profit increasing by 25.5% year-over-year.Total operating expenses were RMB257.9 million (US$37.6 million), compared to RMB294.7 million in the same quarter of last year
SHANGHAI, Sept. 13, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today was informed by co-founders of the Company, Dr. Gang Yu and Mr. Junling Liu, that they have started purchasing shares from time to time from their personal funds during the trading window and intend continue to purchase additional shares. The purchases will be executed on the open market at prevailing market prices, and the co-founders have sole discretion as to how much ADSs they will purchase. The co-founders currently benef
Maintained Operational Profitability for the Second Consecutive QuarterOperating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoYHeld Positive Operating Cash Flow for Two Consecutive QuartersSHANGHAI, Aug. 29, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Net revenues were RMB3.4 billion (US$471.2 million) and gross segment profit (1) was RMB 207.6 million
SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst of Water Tower Research ("WTR") on Thursday, September 5, 2024 at 11:00 a.m. ET. Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, will discuss the Company's Q2 2024 earnings, strategic plans and goals for the second half of 2024, and the latest advancements in technology innovations and the role of AI in
SHANGHAI, July 29, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2024, before the U.S. market opens on Thursday, August 29, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 29, 2024 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Second Quarter 2024 Earnings Co
SHANGHAI, July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced the appointment of Grant Thornton Zhitong Certified Public Accountants LLP ("Grant Thornton") as the Company's independent registered public accounting firm, effective July 19, 2024, replacing Deloitte Touche Tohmatsu Certified Public Accountants LLP. The change of the Company's independent registered public accounting firm was made after a careful and thorough evaluation process and has been approved by 111's boar
SHANGHAIJuly 17, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst of Water Tower Research ("WTR") on Thursday, July 18, 2024 at 2:00 p.m. ET. Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, will discuss the Company's business model, strategic goals, competitive landscape and advantages as well as its growth drivers and market opportunities. To register for this listen-o
SHANGHAI, June 11, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, announced that the Company has entered into a strategic direct supply partnership (the "Partnership") with Beijing Scrianen Pharmaceutical Co., Ltd. ("Scrianen"), a comprehensive pharmaceutical enterprise that integrates research and development, production and marketing. The signing ceremony of the Partnership was attended by Dr. Gang Yu, co-founder and executive chairman of 111, Bin Yi, chairman of Scrianen, and senior managemen
Turned to Quarterly Operational Profitability for the First TimeOperating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoY to 5.8%Achieved Positive Operating Cash FlowSHANGHAI, May 23, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Net revenues were RMB3.5 billion (US$488.7 million) and Gross segment profit (1) was RMB 208.5 million (US$ 28.9 million). Due to
SHANGHAI, April 30, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2024, before the U.S. market opens on Thursday, May 23, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, May 23, 2024 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. First Quarter 2024 Earnings Conference CallRegistration Link: https:/
SHANGHAI, March 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Highlights Net revenues were RMB4.1 billion (US$578.7 million), representing a decrease of 1.0% year-over-year.Gross segment profit (1) was RMB 214.3 million (US$ 30.2 million), decreased by 15.5% year-over-year.Total operating expenses were RMB420.8 million (US$59.3 million), compared to RMB361.9 million in the same quarter of last y
6-K - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
20-F - 111, Inc. (0001738906) (Filer)
NT 20-F - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
6-K - 111, Inc. (0001738906) (Filer)
SC 13D/A - 111, Inc. (0001738906) (Subject)
SC 13D/A - 111, Inc. (0001738906) (Subject)
SC 13D/A - 111, Inc. (0001738906) (Subject)
SC 13D - 111, Inc. (0001738906) (Subject)
SC 13G/A - 111, Inc. (0001738906) (Subject)
SC 13G/A - 111, Inc. (0001738906) (Subject)
SC 13G/A - 111, Inc. (0001738906) (Subject)
SHANGHAI, July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced the appointment of Grant Thornton Zhitong Certified Public Accountants LLP ("Grant Thornton") as the Company's independent registered public accounting firm, effective July 19, 2024, replacing Deloitte Touche Tohmatsu Certified Public Accountants LLP. The change of the Company's independent registered public accounting firm was made after a careful and thorough evaluation process and has been approved by 111's boar
SHANGHAI, Sept. 23, 2022 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), consisting of three independent directors, Mr. Jian Sun, who is the chairman of the Special Committee, Mr. Nee Chuan Teo and Mr. Jun Luo, established by the Company's Board of Directors (the "Board") has retained Houlihan Lokey China Limited as its independent financial advisor and Kirkland & Ellis as its U.S. legal counsel in connection with its review and evaluation of the previously announced preliminary non-binding proposal letter dated September 9, 2022 (the "Proposal")
111, Inc. leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, announced that the Company has entered into a strategic direct supply partnership (the "Partnership") with Beijing Scrianen Pharmaceutical Co., Ltd. ("Scrianen"), a comprehensive pharmaceutical enterprise that integrates research and development, production and marketing.
111 (NASDAQ:YI) reported quarterly Adj Loss per ADS of $(0.02). This is unchanged from the same period last year. The company reported $488.68 million in sales this quarter. This is a 9.22 percent decrease over sales of $538.29 million the same period last year.
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. • InflaRx (NASDAQ:IFRX) is projected to report quarterly loss at $0.20 per share on revenue of $1.42 million. • Fennec Pharmaceuticals (NASDAQ:FENC) is likely to report quarterly loss at $0.02 per share on revenue of $8.67 million. • Welltower (NYSE:WELL) is likely to report quarterly earnings at $0.00 per share on revenue of $218.97 million. • VerifyMe (NASDAQ:VRME) is expected to report quarterly loss at $0.03 per share on revenue of $8.95 million. • Academy Sports (NASDAQ:ASO) is expected to report quarterly earnings at $2.2
111 (NASDAQ:YI) reported quarterly losses of $(0.08) per share. This is unchanged from the same period last year. The company reported $578.69 million in sales this quarter. This is a 3.78 percent decrease over sales of $601.44 million the same period last year.
111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it has received a notice dated Feburary 27, 2024 on behalf of the consortium comprising Dr. Gang Yu, co-founder and co-chairman of the Company, Mr. Junling Liu, co-founder, co-chairman and chief executive officer of the Company and certain other investors (collectively, the "Consortium"), stating that the Consortium would withdraw its preliminary non-binding going private proposal dated September 9, 2022 and preliminary non-binding going private proposal dated October 29, 2022 (collec
The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) On Dec. 20, AgriFORCE Growing Systems filed for an offering of up to 8.72 milli
Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its third quarter. • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.45 per share on revenue of $249.41 million. • Burning Rock Biotech (NASDAQ:BNR) is estimated to report earnings for its third quarter. • Kirkland's (NASDAQ:KIRK) is projected to report quarterly loss at $0.53 per share on revenue of $121.00 million. • Duluth Holdings (NASDAQ:DLTH) is expected to report quarterly loss at $0.26 per share on revenue of $141.47 million. • Big Lots (NYSE:BIG) is projected to report quarterly loss at $4.66 per share on revenue of $1.03 billion. • Academy Sports (NASDAQ:ASO) is expe